The increasing incidence of respiratory conditions like asthma, COPD, and bronchitis mainly drives the growth of the inhalable drugs market. Additionally, the rising prevalence of diabetes and ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.